The University of Southampton
University of Southampton Institutional Repository

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial
Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial

Background: pertussis vaccination in pregnancy is recommended in many countries to provide protection to young infants. The best timing for this vaccination is uncertain. In the UK, vaccination is recommended between 16 weeks and 32 weeks of gestation. In this trial we aimed to investigate the equivalence of three time periods for pertussis vaccination in pregnancy.

Methods: in this open-label, equivalence, randomised controlled trial to investigate equivalence of different time windows for pertussis vaccination in pregnancy, participants were randomly assigned (1:1:1 ratio) to receive a pertussis-containing vaccine (Boostrix-inactivated poliovirus vaccine) in one of three gestational age groups, comprising group 1 (≤23 weeks + 6 days), group 2 (24-27 weeks + 6 days), and group 3 (28-31 weeks + 6 days) using a computer-generated randomisation list. The primary outcome was concentration of pertussis-specific antibodies in the infant born at term at birth. Maternal blood sampling was done before and 2 weeks after vaccination and at delivery, together with a cord sample, and an infant sample was collected at least 4 weeks after primary vaccination. Reactogenicity was assessed for 7 days after vaccination. This trial was registered with ClinicalTrials.gov (NCT03908164).

Findings: between May 7, 2019, and Feb 13, 2020, of 1010 women assessed for eligibility, 364 women were recruited and 351 received the intervention (120 in group 1, 119 in group 2, and 112 in group 3). Equivalence of time periods was demonstrated for anti-pertussis toxin and anti-pertactin IgG concentrations. The cord blood geometric mean concentrations of anti-filamentous haemagglutinin IgG were higher with increasing gestational age at vaccination, such that for infants in group 1 (≤23 weeks + 6 days), equivalence to group 3 (28-31 weeks + 6 days) was not shown. Reported rates of fever were similar between study groups.

Interpretation: pertussis vaccination at three different time intervals in pregnancy resulted in equivalent concentrations of IgG antibodies in infants against two of the three pertussis antigens assessed. Overall, these findings support recommendations to vaccinate any time between 16 weeks and 32 weeks of gestation.

Funding: the Thrasher Research Fund and the National Immunisation Schedule Evaluation Consortium through the National Institute for Health and Care Research policy research programme.

e300-e308
Calvert, Anna
2a51489e-8ea4-4b6c-a439-ef1df57999bb
Amirthalingam, Gayatri
483455da-eee7-43d0-9252-1acfad58aa2c
Andrews, Nick
7d63cec1-f343-4e37-83b3-8f80e4022ed4
Basude, Sneha
36d9a9f9-3345-4c3c-bb34-36cabad17931
Coleman, Matthew
9f08417a-9367-4e8a-8d6a-d86b47c39007
Cuthbertson, Hannah
a2ed2e68-bad2-4215-8170-7347ccaa08eb
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Greening, Vanessa
d28d85e8-299d-4191-90cf-eeff7e3f48a9
Hallis, Bassam
f6388da1-bf85-457f-b30a-c0849034024c
Johnstone, Edward
a87342b6-24bf-43bd-bbc4-3e4d6e0d9ae5
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426
Karampatsas, Konstantinos
57cce5e6-8dca-4cdb-84d4-6551f227125f
Khalil, Asma
b1f0d35b-6e04-4b2a-acfb-8aaac887d512
Le Doare, Kirsty
9424dc5c-4484-41d3-86dd-29cfaffb43f5
Matheson, Mary
00059ccd-6077-42af-a8a2-a3c3b31e5eca
Peregrine, Elisabeth
e7fce814-e477-4330-87c3-64be6aa026d7
Snape, Matthew D.
184fac36-63b2-40d2-be21-c972f41d07ab
Vatish, Manu
ac1a9892-c0c2-49c7-b835-12173afdfe50
Heath, Paul T.
c1874f54-5279-4438-99f2-a0ca9ded7800
OpTIMUM Study Group
Calvert, Anna
2a51489e-8ea4-4b6c-a439-ef1df57999bb
Amirthalingam, Gayatri
483455da-eee7-43d0-9252-1acfad58aa2c
Andrews, Nick
7d63cec1-f343-4e37-83b3-8f80e4022ed4
Basude, Sneha
36d9a9f9-3345-4c3c-bb34-36cabad17931
Coleman, Matthew
9f08417a-9367-4e8a-8d6a-d86b47c39007
Cuthbertson, Hannah
a2ed2e68-bad2-4215-8170-7347ccaa08eb
England, Anna
590a306a-2173-4799-80b8-d09e44854f59
Greening, Vanessa
d28d85e8-299d-4191-90cf-eeff7e3f48a9
Hallis, Bassam
f6388da1-bf85-457f-b30a-c0849034024c
Johnstone, Edward
a87342b6-24bf-43bd-bbc4-3e4d6e0d9ae5
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426
Karampatsas, Konstantinos
57cce5e6-8dca-4cdb-84d4-6551f227125f
Khalil, Asma
b1f0d35b-6e04-4b2a-acfb-8aaac887d512
Le Doare, Kirsty
9424dc5c-4484-41d3-86dd-29cfaffb43f5
Matheson, Mary
00059ccd-6077-42af-a8a2-a3c3b31e5eca
Peregrine, Elisabeth
e7fce814-e477-4330-87c3-64be6aa026d7
Snape, Matthew D.
184fac36-63b2-40d2-be21-c972f41d07ab
Vatish, Manu
ac1a9892-c0c2-49c7-b835-12173afdfe50
Heath, Paul T.
c1874f54-5279-4438-99f2-a0ca9ded7800

Calvert, Anna, Amirthalingam, Gayatri, Andrews, Nick, Basude, Sneha and Coleman, Matthew , OpTIMUM Study Group (2023) Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial. The Lancet Microbe, 4 (5), e300-e308. (doi:10.1016/S2666-5247(22)00332-9).

Record type: Article

Abstract

Background: pertussis vaccination in pregnancy is recommended in many countries to provide protection to young infants. The best timing for this vaccination is uncertain. In the UK, vaccination is recommended between 16 weeks and 32 weeks of gestation. In this trial we aimed to investigate the equivalence of three time periods for pertussis vaccination in pregnancy.

Methods: in this open-label, equivalence, randomised controlled trial to investigate equivalence of different time windows for pertussis vaccination in pregnancy, participants were randomly assigned (1:1:1 ratio) to receive a pertussis-containing vaccine (Boostrix-inactivated poliovirus vaccine) in one of three gestational age groups, comprising group 1 (≤23 weeks + 6 days), group 2 (24-27 weeks + 6 days), and group 3 (28-31 weeks + 6 days) using a computer-generated randomisation list. The primary outcome was concentration of pertussis-specific antibodies in the infant born at term at birth. Maternal blood sampling was done before and 2 weeks after vaccination and at delivery, together with a cord sample, and an infant sample was collected at least 4 weeks after primary vaccination. Reactogenicity was assessed for 7 days after vaccination. This trial was registered with ClinicalTrials.gov (NCT03908164).

Findings: between May 7, 2019, and Feb 13, 2020, of 1010 women assessed for eligibility, 364 women were recruited and 351 received the intervention (120 in group 1, 119 in group 2, and 112 in group 3). Equivalence of time periods was demonstrated for anti-pertussis toxin and anti-pertactin IgG concentrations. The cord blood geometric mean concentrations of anti-filamentous haemagglutinin IgG were higher with increasing gestational age at vaccination, such that for infants in group 1 (≤23 weeks + 6 days), equivalence to group 3 (28-31 weeks + 6 days) was not shown. Reported rates of fever were similar between study groups.

Interpretation: pertussis vaccination at three different time intervals in pregnancy resulted in equivalent concentrations of IgG antibodies in infants against two of the three pertussis antigens assessed. Overall, these findings support recommendations to vaccinate any time between 16 weeks and 32 weeks of gestation.

Funding: the Thrasher Research Fund and the National Immunisation Schedule Evaluation Consortium through the National Institute for Health and Care Research policy research programme.

Text
1-s2.0-S2666524722003329-main - Version of Record
Available under License Creative Commons Attribution.
Download (739kB)

More information

e-pub ahead of print date: 17 April 2023
Published date: 3 May 2023
Additional Information: We gratefully acknowledge all of the participants of the study and the clinical teams at the participating sites. This study is an independent research study funded by the Thrasher Research Fund (award number 14390) and the National Immunisation Schedule Evaluation Consortium (NISEC) through the National Institute for Health and Care Research policy research programme (award ID PR-R17-0916-22001). The views expressed are those of the authors and not necessarily those of the NISEC or the National Institute for Health and Care Research policy research programme.

Identifiers

Local EPrints ID: 476992
URI: http://eprints.soton.ac.uk/id/eprint/476992
PURE UUID: 32dd0bca-cdbe-4c72-b6d9-5a55abfc4432
ORCID for Christine E. Jones: ORCID iD orcid.org/0000-0003-1523-2368

Catalogue record

Date deposited: 23 May 2023 16:33
Last modified: 17 Mar 2024 03:45

Export record

Altmetrics

Contributors

Author: Anna Calvert
Author: Gayatri Amirthalingam
Author: Nick Andrews
Author: Sneha Basude
Author: Matthew Coleman
Author: Hannah Cuthbertson
Author: Anna England
Author: Vanessa Greening
Author: Bassam Hallis
Author: Edward Johnstone
Author: Konstantinos Karampatsas
Author: Asma Khalil
Author: Kirsty Le Doare
Author: Mary Matheson
Author: Elisabeth Peregrine
Author: Matthew D. Snape
Author: Manu Vatish
Author: Paul T. Heath
Corporate Author: OpTIMUM Study Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×